Home＞REGULATORY
Japan’s “NDB” Insurance Claim Database Corroborates Slack SGLT-2 Prescriptions for Older People in FY2015(Sep.26.2017)
By Reiji Anasako
The pharma industry has seen floundering sales of sodium-glucose co-transporter-2 (SGLT-2) inhibitors in Japan ever since their launch a few years ago. Now with recent statistics based on a national insurance claim database, dubbed NDB, it was revealed that doctors were indeed shying away from prescribing these medicines in the elderly age 75 and older amid swirling side effect concerns over the class ...
(LOG IN FOR FULL STORY)
The pharma industry has seen floundering sales of sodium-glucose co-transporter-2 (SGLT-2) inhibitors in Japan ever since their launch a few years ago. Now with recent statistics based on a national insurance claim database, dubbed NDB, it was revealed that doctors were indeed shying away from prescribing these medicines in the elderly age 75 and older amid swirling side effect concerns over the class ...
-
-
Lawmakers Question Rationale for PMD Law Amendment as LDP Launches Debate
Jul.19
- Scope of Japan-EU GMP Mutual Recognition Agreement for Pharmaceuticals Expanded: MHLW Jul.19
- Boehringer’s DPP-4/SGLT2 Combo Up for MHLW Panel Review on July 27 Jul.17
- MHLW to Introduce Guidelines for Sales Reps’ Activities, Calling for the Creation of Supervising Offices Jul.17
-
New Medical Infrastructure Law to Pave Way for Database on 50 Million People: Govt Official
Jul.13
- J-TEC Submits Trial Protocol for Autologous Cultured Cartilage in Knee Osteoarthritis Use(Jul.20)
- Toray, Bonac to Begin US PI Trial of Nucleic Acid for IPF(Jul.20)
- Subcutaneous Vedolizumab Hits Primary Endpoint in PIII: Takeda(Jul.20)
- Takeda, Ovid Launching 3 New Studies for Rare Epilepsy Drug(Jul.20)
- Steep Hikes in Prices of Chinese-Made APIs Could Hit Generic Makers Hard(Jul.20)
